SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : taxloss selling -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (12)10/16/2000 7:13:21 PM
From: tom pope  Respond to of 16
 
>>They don't want to be in the sad position of making holders pay tax when the overall portfolio might be down.
<<

They've done it to me, and didn't seem to be particularly sad. Which is why I don't favor actively managed funds any more.



To: Biomaven who wrote (12)10/18/2000 11:24:14 AM
From: Extra Pale  Respond to of 16
 
Peter,
Thanks for the reminder about 10/31 fund year end. Bought INCY & INCY 3/01 calls -- per yahoo, INCY has cash of $625 million out of a market cap of $1800m; 63% institutional ownership; currently selling at ~20% of annual high. More importantly, has strong revenue growth and a very valuable IP portfolio plus a coherent business plan. Seems to be a lot of upside in this stock, especially at under $30/share.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News